![Novartis AG Website](https://cdn.finchat.io/382553.png)
Novartis AG
SWX-NOVN
Company Overview
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Name
Novartis AG
CEO
Dr. Vasant Narasimhan M.D.
Website
www.novartis.com
Sector
Pharmaceuticals
Year Founded
1996
Profile
Market Cap
CHF 199.62B
EV
CHF 218.25B
Shares Out
2,024.58M
Revenue
$48.86B
Employees
76,057
Margins
Gross
75.55%
EBITDA
39.49%
Operating
30.25%
Pre-Tax
22.31%
Net
33.1%
FCF
28.47%
Returns (5Yr Avg)
ROA
10.54%
ROTA
54.71%
ROE
22.87%
ROCE
13.5%
ROIC
9.23%
Valuation (TTM)
P/E
—
P/B
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
EV/Gross Profit
—
Valuation (NTM)
Price Target
CHF 98.54
P/E
—
PEG
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
Financial Health
Cash
$8,431M
Net Debt
$20.56B
Debt/Equity
0.69
EBIT/Interest
16.31
Growth (CAGR)
Rev 3Yr
-1.77%
Rev 5Yr
0.88%
Rev 10Yr
-0.91%
Dil EPS 3Yr
25.68%
Dil EPS 5Yr
9.99%
Dil EPS 10Yr
7.14%
Rev Fwd 2Yr
6.95%
EBITDA Fwd 2Yr
8.53%
EPS Fwd 2Yr
12.08%
EPS LT Growth Est
8.98%
Dividends
Yield
—
Payout
79.57%
DPS
$3.92
DPS Growth 3Yr
4.94%
DPS Growth 5Yr
6.65%
DPS Growth 10Yr
3.6%
DPS Growth Fwd 2Yr
1.28%